Results 81 to 90 of about 72,883 (309)

COLLAB: A Global Survey of Clinical and Laboratory Assessment in Alopecia Areata by Hair Specialists

JEADV Clinical Practice, EarlyView.
ABSTRACT Background Alopecia areata (AA) is a common non‐scarring alopecia. Data continue to emerge on associations with autoimmune and other conditions. Janus kinase inhibitors (JAKi) are increasingly used to treat AA. Objectives The aim was to assess variation in laboratory testing in patients with AA among hair experts internationally and to compare
Cathal O'Connor, Aoife Boyle, Leila Asfour, Bevin Bhoyrul, Laita Bokhari, George Cotsarelis, Chantal Cotter, Brittany Craiglow, Lara Cutlar, Rachita Dhurat, Ncoza Dlova, Isabella Doche, Jeff Donovan, Aaron M. Drucker, Samantha Eisman, Daniel Fernandes Melo, Matthew J. Harries, Maria Hordinsky, Ahmed Kazmi, Brett King, Antonios Kolios, Nekma Meah, Paradi Mirmirani, Arash Mostaghimi, Manabu Ohyama, Yuliya Ovcharenko, Rodrigo Pirmez, Bianca Maria Piraccini, Lidia Rudnicka, David Saceda‐Corralo, Jerry Shapiro, Cathryn Sibbald, Rod Sinclair, Blake R. C. Smith, Michela Starace, Sergio Vaño‐Galván, Wei Liang Koh, Katherine York, Ian McDonald, Dmitri Wall   +39 more
wiley   +1 more source

A case of new-onset vitiligo in a patient on tofacitinib and brief review of paradoxical presentations with other novel targeted therapies [PDF]

, 2020
With recent advancements in the understanding of vitiligo pathogenesis, Janus kinase (JAK) inhibitors have emerged as a promising new treatment modality, but their effects remain incompletely elucidated.
Alikhan, Mujahed, Jogi, Reena, Nguyen, Julie K, Patel, Anisha B, Schlichte, Megan J   +4 more
core  

Rates of Infections, Malignancies, Cardiovascular Outcomes, and Death in Individuals with Hospital-treated Alopecia Areata: A Registry-based Cohort Study in Denmark

Acta Dermato-Venereologica
The emergence of new systemic treatments for alopecia areata underscores the importance of estimating rates of potential treatment safety events among individuals with alopecia areata.
Sissel Brandt Toft Sørensen, Prethibha George, Oladayo Jagun, Robert Wolk, Lynne Napatalung, Samuel H. Zwillich, Lars Iversen, Vera Ehrenstein   +7 more
doaj   +1 more source

Case Report of a Patient With Psoriasis Vulgaris, Psoriatic Arthritis and Alopecia Universalis Successfully Treated With Tofacitinib and Methotrexate

JEADV Clinical Practice, EarlyView.
We present a case of a 31‐year‐old female with alopecia universalis, psoriasis vulgaris, and psoriatic arthritis, who showed poor response to prior treatments. Following the initiation of a combination therapy with tofacitinib and methotrexate, significant improvements in joint pain and hair regrowth were observed.
Jan Nicolai Wagner, Matthias Augustin, Caroline Gewiss, Carolin Grote, Nesrine Ben‐Anaya   +4 more
wiley   +1 more source

The Importance of Readability: A Guide to Understanding Alopecia Areata through Multilingual Online Resources

Acta Dermato-Venereologica
Online resources play a vital role in patient education, yet the readability of alopecia areata-related materials remained understudied. A thorough analysis of online alopecia areata-related materials across 5 languages was conducted using Google search.
Tomasz Skrzypczak, Anna Skrzypczak, Jacek C. Szepietowski   +2 more
doaj   +1 more source

А choice of therapy for severe forms of alopecia area [PDF]

Vestnik Dermatologii i Venerologii
Alopecia areata is a chronic organ-specific autoimmune inflammatory disease with a genetic predisposition. Alopecia areata is characterized by damage to hair follicles, persistent or temporary non-scarring hair loss.
Yulia A. Gallyamova
doaj   +1 more source

Post-Partum Pituitary Insufficiency and Livedo Reticularis Presenting a Diagnostic Challenge in a Resource Limited Setting in Tanzania: A Case Report, Clinical Discussion and Brief Review of Existing Literature. [PDF]

, 2012
Pituitary disorders following pregnancy are an important yet under reported clinical entity in the developing world. Conversely, post partum panhypopituitarism has a more devastating impact on women in such settings due to high fertility rates, poor ...
A Cénac, A Gutenberg, A Lecube, AH Zargar, C Ajith, D Castle, EH Sidibe, EM Tan, F Bakiri, Faheem G Sheriff, GK Leung, H Raff, HC Lee, J Honegger, JD Ji, JR Ouma, Kajiru G Kilonzo, ME Molitch, N Tubridy, P Caturegli, R Golden, R Goswami, RA Kristof, S Diederich, William P Howlett, Y Ozawa, Z Karaca, ZA Erkut   +27 more
core   +3 more sources

Rapidly progressive alopecia areata totalis in a COVID‐19 patient, unresponsive to tofacitinib

Journal of the European Academy of Dermatology and Venereology, 2021
Alopecia areata (AA) is a common autoimmune disease characterized by non-scarring hair loss. (1) Tofacitinib is an effective oral JAK 1/3 inhibitor that can block IL-2, IL-7 and IL-6 and is reported as an option for alopecia areata treatment.(2,3) Though
S. Ferreira, M. Dias, R. Berbert Ferreira, A. C. Neves Neto, R. Trüeb, O. Lupi   +5 more
semanticscholar   +1 more source

Trichoscopy criteria for diagnosing female androgenic alopecia. [PDF]

, 2008
Differential diagnosis of chronic hair loss remains a challenge in dermatology. The aim of the study was to evaluate the value of a new scalp visualization technique, trichoscopy, in differential diagnosis of hair loss.
Adriana Rakowska, Elzbieta Kowalska-Oledzka, Lidia Rudnicka, Malgorzata Olszewska, Monika Slowinska   +4 more
core   +1 more source

Use of 5% Topical Minoxidil Application for Telogen Effluvium: An Open‐Label Single‐Arm Clinical Trial

The Journal of Dermatology, EarlyView.
ABSTRACT Telogen effluvium (TE) is an acute and diffuse hair loss due to an abnormal increase in telogen hair follicles in response to external or internal factors. Recently, TE attracts global interest as a major cause of hair loss as a sequela of COVID‐19.
Manabu Ohyama, Ryokichi Irisawa, Masaki Uchiyama, Miho Mori, Kazuhiro Aoki, Yuto Ueda, Toru Fujita   +6 more
wiley   +1 more source